key: cord-0708882-b2y9a0mp
authors: Pandey, Pratikshya; Al Rumaih, Zahrah; Kels, Ma. Junaliah Tuazon; Ng, Esther; Rajendra, KC; Malley, Roslyn; Chaudhri, Geeta; Karupiah, Gunasegaran
title: Simultaneous therapeutic targeting of inflammation and virus ameliorates influenza pneumonia and protects from morbidity and mortality
date: 2022-02-10
journal: bioRxiv
DOI: 10.1101/2022.02.09.479486
sha: 3bda85a039caae207df0f11b44f98110affaa06f
doc_id: 708882
cord_uid: b2y9a0mp

Pneumonia is a severe complication caused by inflammation of the lungs following infection with seasonal and pandemic strains of influenza A virus (IAV) that can result in lung pathology, respiratory failure and death. There is currently no treatment available for severe disease and pneumonia caused by IAV. Antivirals are available, but they are far from satisfactory if treatment is not initiated within 48 hours of symptoms onset. Influenza complications and mortality are often associated with high viral load and excessive lung inflammatory cytokine response. Therefore, we simultaneously targeted IAV with the antiviral drug oseltamivir and inflammation with the anti-inflammatory drug etanercept, targeting TNF after the onset of clinical signs to treat IAV pneumonia effectively. The combined treatment effectively reduced lung viral load, lung pathology, morbidity and mortality during respiratory IAV infection in mice, contemporaneous with significant downregulation of the inflammatory cytokines TNF, IL-1β, IL-6, IL-12p40, chemokines CCL2, CCL5 and CXCL10 and dampened STAT3 activation. Consequently, combined therapy with oseltamivir and a STAT3 inhibitor also effectively reduced clinical disease and lung pathology. Combined treatment using either of the anti-inflammatory drugs and oseltamivir dampened an overlapping set of cytokines. Thus, combined therapy targeting a specific cytokine or cytokine signaling pathway plus an antiviral drug provides an effective treatment strategy for ameliorating IAV pneumonia. Effective treatment of IAV pneumonia required multiple doses of etanercept and a high dose of oseltamivir. This approach might apply to the treatment of pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Significance Statement Antivirals against influenza A virus (IAV) are ineffective in treating pneumonia if administered 48 h after onset of disease symptoms. The host inflammatory response and tissue damage caused by IAV are responsible for lung pathology. We reasoned that targeting both virus and inflammation would be more effective in reducing lung pathology and pneumonia, morbidity and mortality. The simultaneous treatment with an anti-inflammatory drug targeting TNF or STAT3, combined with the anti-IAV antiviral drug, oseltamivir, significantly improved clinical disease, reduced lung viral load and pathology, and protected mice from severe pneumonia. The combined treatment suppressed multiple pro-inflammatory cytokines and cytokine signaling pathways. Thus, after the onset of disease symptoms, both virus and inflammation must be targeted to treat IAV pneumonia effectively.

and pandemic strains of influenza A virus (IAV) that can result in lung pathology, respiratory failure and 23 death. There is currently no treatment available for severe disease and pneumonia caused by IAV. Antivirals 24 are available, but they are far from satisfactory if treatment is not initiated within 48 hours of symptoms 25 onset. Influenza complications and mortality are often associated with high viral load and excessive lung 26 inflammatory cytokine response. Therefore, we simultaneously targeted IAV with the antiviral drug 27 oseltamivir and inflammation with the anti-inflammatory drug etanercept, targeting TNF after the onset of 28 clinical signs to treat IAV pneumonia effectively. The combined treatment effectively reduced lung viral load, 29 lung pathology, morbidity and mortality during respiratory IAV infection in mice, contemporaneous with 30 significant downregulation of the inflammatory cytokines TNF, IL-1β, IL-6, IL-12p40, chemokines CCL2, 31 CCL5 and CXCL10 and dampened STAT3 activation. Consequently, combined therapy with oseltamivir and 32 a STAT3 inhibitor also effectively reduced clinical disease and lung pathology. Combined treatment using 33 either of the anti-inflammatory drugs and oseltamivir dampened an overlapping set of cytokines. Thus, 34 combined therapy targeting a specific cytokine or cytokine signaling pathway plus an antiviral drug provides 35 an effective treatment strategy for ameliorating IAV pneumonia. Effective treatment of IAV pneumonia 36 required multiple doses of etanercept and a high dose of oseltamivir. This approach might apply to the 37 treatment of pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 38 8 comparable body weight losses from days 2-6 p.i. (Supplementary Fig. S2 A and B) . The lung viral load was 153 high (>10 6 PFU) and comparable in both strains of mice (Supplementary, Fig. S2C ). TNF -/mice had 154 significantly higher histopathological scores ( Supplementary Fig. S2D ) due to the more pronounced lung 155 pathological changes compared to WT mice , consistent with a previous report 156 (30) . 157

Etanercept treatment beginning at day 1 p.i. with IAV improved clinical disease and lung pathology (Fig. 1) . 160

However, most patients seek medical attention late after the onset of symptoms (6) . Furthermore, the 161 cytopathic effects of exponentially increasing viral load also contribute to lung injury at that stage of the 162 disease, but etanercept does not affect lung viral load. We reasoned that combined treatment with 163 etanercept and oseltamivir simultaneously would be necessary to minimize disease severity effectively. 164

An oral dose of 150 mg oseltamivir twice daily is well-tolerated in adult humans (31) and is equivalent to a 165 dose of 20 mg/kg in mice administered twice daily (32). Mice infected with 3000 PFU IAV i.n. were given an 166 oral dose of oseltamivir at 20 mg/kg (twice daily; total 40 mg/kg/day), one dose of etanercept, or both drugs 167 (combined) on day 3 p.i. after onset of disease signs. Additional doses of oseltamivir were given on days 4 168 and 5 p.i. All mice were killed on day 6 p.i. Since the clinical course of IAV disease is short in mice, it leaves 169 a very narrow window period for treatment. We commenced treatment from day 3 p.i, so that animals receive 170 appropriate treatment(s) for at least 2 days before they succumb to infection. 9 Oseltamivir or etanercept significantly reduced the levels of mRNA transcripts for TNF, 177 CCL2, . In addition to these cytokines/chemokines, the 178 combined treatment significantly downregulated levels of expression of IL-1b and CXCL10 (Supplementary 179 Fig. S4 B and G) . mTNF levels were significantly reduced by all three treatment regimens (Supplementary 180 Fig. S4H ). IAV infection minimally activated NF-kB p65, but levels were significantly reduced by oseltamivir 181 or combined treatment ( Supplementary Fig. S4I ). On the other hand, STAT3, another critical transcription 182 factor implicated in the host inflammatory response, was highly activated by IAV infection. All three treatment 183 regimens reduced IAV-induced pSTAT3 levels, however, the reduction was modest with etanercept or 184 combined treatments but was significant with oseltamivir treatment alone ( Supplementary Fig. S4J 195 Groups of IAV-infected WT, TM and TNF -/mice were treated with oseltamivir, etanercept or both drugs after 196 onset of disease signs on day 3 p.i., treatment continued on days 4 and 5 p.i. once daily and animals killed 197 at day 6 p.i. TNF -/mice were used as negative controls as they do not respond to etanercept treatment (33) 198 (33). TM mice lack endogenous TNF signaling but respond to etanercept treatment (Fig. 1) . 199

Mock-, etanercept-or oseltamivir-treated WT mice continued to lose weight until day 6 p.i. when animals 200 were killed for various analyses. In contrast, WT mice given the combined treatment stopped losing weight 201 just one day after initiation of treatment and by day 6 p.i., body weight loss in this group was significantly 202 lower than the other groups ( Fig. 2A) . All treatment regimens significantly lowered clinical scores from day 203 4 p.i., but the most significant reduction was in the combined treatment group (Fig. 2B) . Lung viral load was 204 similar in mock, and etanercept treated groups but significantly reduced by oseltamivir or combined 205 treatment compared with the mock-treated group (Fig. 2C) . Notably, once-daily treatment with150 mg/kg 206 oseltamivir alone effectively reduced viral load late after the onset of disease signs. There were significant 207 reductions in lung histopathological scores in etanercept-but not oseltamivir-treated animals compared to 208 mock-treated mice, but the combined treatment showed the most considerable reduction (Fig. 2D) . 209

In IAV-infected TNF -/mice, none of the treatment regimens had any significant effects in reducing weight 210 loss (Fig. 2E ). Mice given oseltamivir or the combined treatment had significantly lower clinical scores than 211 etanercept-or mock-treated animals (Fig. 2F ). Lung viral load and histopathological scores were also 212 reduced by oseltamivir or combined treatment but not by etanercept-or mock treatment ( Fig. 2 G and H) . 213

The reduced viral load likely contributed to the lower clinical and histopathological scores in TNF -/mice. 214 TM mice exhibited apparent beneficial effects from the single or combined treatment regimens, similar to 215 observations made in WT mice ( Fig. 2 I-L) . On day 6 p.i., etanercept treatment reduced weight loss 216 compared to mock treatment, but the effect was more pronounced in oseltamivir or combined treatment 217 groups (Fig. 2I ). All treatment regimens significantly reduced clinical scores, with the combined treatment 218 having the most prominent effect (Fig. 2J ). Oseltamivir or combined treatment, but not etanercept, reduced 219 lung viral load (Fig. 2K ). Lung histopathological scores were significantly reduced by oseltamivir or 220 etanercept monotherapy, but the combined treatment reduced it to a substantially greater extent (Fig. 2L) . 221

Microscopic examination of lung histological sections revealed dramatic reductions in parenchymal edema 222 and damage to bronchial and alveolar walls in WT mice given the combined treatment compared to the 223 other treatment groups ( Fig. 3 A-H) . Focal leukocyte infiltration was most abundant in lungs of WT mice 224 given mock-treatment compared with oseltamivir-or etanercept-treated groups, but it was only moderate in 225 mice given the combined therapy ( Fig. 3 A-H) . In TNF -/mice, IAV-induced lung edema and inflammatory 226 cell recruitment, were reduced by oseltamivir or combined treatment, but not by etanercept (Fig. 3 I-P) . 227

However, the extent of improvements was less compared to WT mice. All treatment regimens ameliorated 228 11 edema and inflammatory cell infiltration in TM mice, except for mock treatment, but the degree of 229 improvement was highest in the combined-treated group (Fig. 3 

To obtain an insight into the mechanisms through which treatment with etanercept combined with a higher 231 dose of oseltamivir, both administered daily ( Fig. 2 and 3) , we focused on the effects of treatment on 232 inflammatory cytokine and chemokine mRNA transcript levels using lung tissue samples from the 233 experiment described in Fig. 2 . 234

Compared to mock treatment, etanercept or oseltamivir reduced mRNA transcripts for TNF, IL-1β, and IL-235 12p40 ( Fig. 4 A, B and C) , whereas the combined treatment was more effective in decreasing the levels of 236 those cytokines as well as IL-6 and the chemokines CCL2, CCL5, and CXCL10 (Fig. 4 D-G) . Levels of 237 mTNF were decreased marginally by etanercept but significantly by oseltamivir or the combined treatment 238 ( Fig. 4H ). All treatment regimens reduced levels of activated phosphorylated (p) NF-kB p65 (pNF-kB p65) 239

protein, but only oseltamivir treatment was significant (Fig. 4I ). However, protein levels of pSTAT3 were 240 reduced only by oseltamivir or the combined treatment but not etanercept (Fig. 4J) . 241

Taken together, the effectiveness of the combined treatment regimen in reducing weight loss, clinical 242 disease, lung pathology and viral load was associated with significant reductions in TNF, IL-1β, IL-6, IL-243 12p40, CCL2, CCL5 and CXCL10 and to some extent pSTAT3. It was evident that the higher dose of 244 oseltamivir resulted in significant reductions in viral load and levels of IL-1β more effectively (Fig. 4 ) 245 compared to treatment with a lower dose oseltamivir ( Supplementary Fig. S4 ). 246

We determined whether the higher dose of oseltamivir administration in the combined treatment regimen 249 afforded protection against influenza pneumonia, and lethal disease. IAV-infected mice were treated with 250 high dose oseltamivir, etanercept or both drugs after the onset of disease signs at day 3 p.i. once daily for 251 up to 20 days. Animals were monitored for morbidity and mortality until day 21 p.i. when all surviving animals 252 were killed. TNF -/mice, which do not respond to etanercept treatment ( Fig. 2) were infected and treated 253 similarly for use as controls. 254

Both WT and TNF -/mice infected with IAV continued to lose weight from day 2 p.i. and exhibited clinical 255 signs of disease from day 3 p.i. (Fig. 5 A-D) . All mock-treated WT mice succumbed to infection and were 256 killed for ethical reasons by day 6 p.i. Etanercept treatment prolonged survival by 1 day in 4 of 5 (80%) IAV-257 infected WT mice (Fig. 5E ). Oseltamivir treatment alone protected 1 of 5 (20%) mice from lethal IAV infection 258 while the remaining animals succumbed on days 6 and 7 p.i. Mice given the combined treatment had the 259 highest survival rate wherein one mouse succumbed to the infection on day 11 p.i. but 80% of animals 260 survived until day 21 when they were killed (Fig. 5E ). Mock-treated TNF -/mice succumbed to the infection 261 on days 5 or 6 p.i. (Fig. 5F ) and there were no beneficial effects of etanercept, oseltamivir or the combined 262 therapies as all IAV-infected animals succumbed by day 7 p.i. 263

Data presented in the preceding section indicated that viral load in WT mice was significantly reduced by 264 oseltamivir alone or combined treatment regimens (Fig. 2C ). However, a greater proportion of mice in the 265 combined treatment group survived (Fig. 5E ). It was clear that although high dose oseltamivir was effective 266

in reducing viral load late after the onset of disease signs, it alone was insufficient to protect against influenza 267 pneumonia, morbidity or mortality. Thus, both virus and inflammation must be targeted simultaneously to 268 afford protection against influenza pneumonia. 269

The STAT3 pathway is downstream of the NF-kB pathway, and dysregulated TNF levels cause 272 hyperactivation of STAT3, which also correlated with severe pneumonia during respiratory ectromelia virus 273 (ECTV) infection (26, 27) . ECTV causes mousepox, a surrogate mouse model for smallpox caused by the 274 variola virus in humans (34). Treatment of ECTV-infected mice with a selective STAT3 inhibitor, SI-301, 275 significantly reduced lung pathology, but it was insufficient to protect the animals (26). However, inhibition 276 of STAT3 combined with an antiviral drug, cidofovir, significantly reduced clinical disease and viral load and 277 ameliorated lung pathology (33). The reduced morbidity was associated with reductions in inflammatory 278 cytokine/chemokine gene/protein expression. We hypothesized that a similar approach of simultaneous 279 targeting of virus and the STAT3 signaling pathway might also be effective in the IAV pneumonia model. 280

Although the standard dose of oseltamivir (40 mg/kg) was ineffective in reducing viral load when combined 281 with etanercept ( Supplementary Fig. S3D ), we first investigated whether it would be effective in reducing 282 morbidity when combined with S3I-201. Mice infected with IAV were given 20 mg/kg oseltamivir orally twice 283 daily, 5mg/kg S3I-201 via the i.p. route or a combination of both drugs beginning on day 3 after the onset of 284 disease signs, and treatment continued on days 4 and 5 p.i. All animals were killed on day 6 p.i. 285

The combined treatment significantly reduced weight loss, clinical scores, and lung histopathological scores 286 but did not affect lung viral load ( Supplementary Fig. S5 A-I). SI-301 had no effect on weight loss or viral 287 load but reduced the clinical and histopathological scores. Mechanistically, oseltamivir reduced mRNA 288 levels for IL-1b and IL-12p40 and protein levels of mTNF and pNF-kB ( Supplementary Fig. S6 We next investigated whether the combined treatment regimen with S3I-201 and high dose oseltamivir 295 would be more effective in reducing morbidity. Groups of IAV infected mice were treated with 150 mg/kg 296 oseltamivir, 5mg/kg S3I-201 or both drugs (combined) on days 3 and 4 p.i. after the onset of disease signs. 297

Since one of the mock-treated animals was severely moribund, all mice were killed on day 5 p.i. for ethical 298 reasons. 299

High dose oseltamivir did not affect weight loss and modestly reduced lung histopathological scores but had 300 a significant impact in reducing clinical scores and lung viral load ( Fig. 6 A-D) . S3I-201 or combined 301 treatment significantly reduced weight loss, clinical scores and lung histopathological scores, while the latter 302 also reduced the lung viral load and was by far the most effective in reducing all parameters measured ( There are no specific treatments for influenza pneumonia other than hospitalization and supportive care. 324

Antivirals against IAV are ineffective against severe influenza and pneumonia if treatment is not initiated 325 within 48 hours of disease symptoms. Most individuals do not seek medical attention within this timeframe 326 (Choi et al, 2018) . There is, therefore, an urgent need to advance therapies that specifically treat severe 327 IAV post-onset of symptoms. This study reports an efficacious approach to treating influenza pneumonia by 328 simultaneous treatment with an antiviral and an anti-inflammatory drug. interferon were found to have little or no effect in reducing disease progression and mortality (44). 340

On the other hand, although strategies to limit or dampen inflammation during IAV infection have shown 341 potential benefits, evidence on clinical benefits from the use of only anti-inflammatory drugs is inconclusive, 342 particularly in hospitalized patients or when the treatment initiation is delayed (14) increase the risk of illness severity and mortality after the onset of disease signs in H1N1 or H5N1 IAV 354 infections in mice and humans (Fig. S1)(1, 9, 51, 52 ). That provided a rationale for the simultaneous 355 targeting of virus replication and host inflammatory response as an approach to reduce morbidity and 356 mortality in IAV infected mice. We co-administered oseltamivir and anti-inflammatory drugs (etanercept or 357 16 SI-301) to reduce lung viral load and pathology and improve survival rates in mice with H1N1 influenza 358 pneumonia. 359

We first focused on TNF, which is produced in the early phases of IAV infection and is associated with 360 illness severity and morbidity in mice (53), swine (54) and human (55) timeframe that closely reflects timeframes when patients present at hospitals. Even before it has developed, 375 treating lung inflammation in humans (even before it has developed) from the day of infection is neither 376 feasible nor practical. However, if exposure to virulent or pandemic strains of IAV is identified very early, 377 then anti-IAV drugs, at a standard recommended dose of 75 mg twice daily, would effectively minimize the 378 risk of severe disease, morbidity and mortality (22). We found that a higher dose of oseltamivir at 150 379 mg/kg/day, but not a standard mouse dose of 40 mg/kg/day (58) effectively reduced the lung IAV load. A 380 higher dose of oseltamivir should be considered for evaluation in a clinical setting, particularly in the milieu 381 of severe lung inflammation when the treatment initiation might be delayed. 382

We made a similar finding when the STAT3 signaling pathway was targeted instead of the TNF/NF-kB 383 pathway to reduce lung inflammation. Combined treatment with S3I-201 and oseltamivir reduced viral load, 384 disease signs and lung pathology in IAV-infected mice through the downregulation of the same set of 385 cytokines and chemokines as combined treatment with etanercept and oseltamivir, i.e., TNF, IL-1b, IL-6, IL-386 12p40, CCL2, CCL5 and CXCL10. These cytokines and chemokines enhance acute phase signaling, recruit 387 inflammatory cells, including neutrophils, monocytes, and T lymphocytes to the site of infection, and trigger 388 secondary cytokine production, resulting in lung inflammation and pathology (7). Thus, blockading 389 cytokine(s) or cytokine signaling pathways combined with antiviral treatment will be expected to reduce 390 leukocyte recruitment into the lung. Indeed, the combined treatment using either etanercept or SI-301 391 significantly reduced leukocyte migration to the lungs as evident histologically. In ECTV-infected mice, 392 combined treatment with etanercept and cidofovir reduced recruitment of inflammatory monocytes to the 393 lung (33). Inflammatory monocytes produce cytokines like IL-1, TNF, IL-6, CCL2 and CXCL10. 394

Various stimuli, including viral infection and inflammatory cytokines, activate the NF-kB and STAT3 signaling 395 pathways. TNF and IL-1 activate NF-kB (59), which enhances cytokine expression, including IL-6, which is 396 a potent inducer of STAT3 activation (13, 60, 61). NF-kB and STAT3 cooperatively regulate the expression 397 of several inflammatory cytokines, such as IL-6, CCL2, CCL5, 63) . A recent study 398 evaluating global chromatin binding has revealed more than 36,000 cis-regulatory regions that can 399 potentially bind to both STAT3 and NF-kB (64). NF-kB and STAT3 can collaboratively induce their target 400 gene expression through direct physiological interaction or cooperative binding at a subset of gene 401 promoters/enhancers (62, 64, 65) . for leukocyte recruitment into the lungs (8, 11, 12). Our results indicated that targeting just one inflammatory 419 cytokine (TNF) or a cytokine signaling pathway (STAT3) is sufficient to ameliorate lung pathology, reduce 420 leukocyte infiltration, and confer protection from an otherwise lethal disease when treated combined with 421

oseltamivir. An important finding in this study is that either etanercept or SI-301 treatment combined with 422 oseltamivir dampened the same set of inflammatory cytokines/chemokines, i.e., TNF, IL-1β, IL-6, IL-12p40, 423 CCL2, CCL5, and CXCL10. We believe that STAT3 inhibition will be more appropriate in individuals who 424 cannot be treated with etanercept due to contraindications to the drug or when TNF may not be the driver 425 of lung inflammation. Indeed, in a model of respiratory OPVX infection in TNF -/mice, combined treatment 426 with cidofovir and SI-301 effectively reduced viral load and lung pathology (33). 427

In summary, combined treatment targeting virus and TNF/NF-kB or STAT3 pathways reduces viral load, 428 clinical illness, and lung pathology in IAV infected mice through downregulation of inflammatory cytokines 429 and chemokines, many of which are implicated in disease severity and lung pathology caused by other 430 respiratory viruses, including OPXV (33) and coronaviruses (70) . Therefore, the focus of clinical 431 management of patients with severe viral pneumonia, associated with high viral load and dysregulated 432 inflammation, should be on effective control of both viral replication and inflammatory cytokine and 433 chemokine responses by the combined antiviral and anti-inflammatory drug treatment approach. More 434 patient-oriented clinical research should be undertaken to test this treatment approach in severe respiratory 435 diseases, in particular those caused by viruses of pandemic potential, which includes IAV and SARS-CoV-436 2. In the latter case, treatment efficacy would significantly increase when antivirals specific to the SARS-437

CoV-2 are available. inoculum was removed and the monolayer was covered with the agar overlay. After 4 days of incubation, 484 the agar overlay was removed and the cells were fixed with 10% formalin followed by staining with 0.1% 485 crystal violet. Viral titers were calculated as PFU/g. For details, see Supplementary Information 

Total protein extraction from the lung tissue and western blot analysis was undertaken as described 509 elsewhere (26). Details on the procedure and antibodies used are included in Supplementary Information,  510 Materials and Methods. 511

Statistical analyses of experimental data, as indicated in the legend to each figure, were performed using 513 appropriate tests to compare results using GraphPad Prism 9 (GraphPad Software, Inc.). A value of P < 514 0.05 was taken to be significant: *, p < 0.05; **, p < 0.01; ***, p <0.001 and ****, p <0.0001. 515 were obtained from mice that were infected and treated as described in Fig. 2 . Briefly, groups of WT, TNF -737 and clinical scores were assessed until day 12 p.i., when all the animals were killed. Lungs were collected 802 for measuring viral load and mRNA transcripts for pro-inflammatory cytokines and chemokines. Data shown 803 in Fig. S1 is presented here as Pearson correlation coefficient (r) between any of the two determinants of 804 disease severity, namely correlation between weight loss and lung viral load or mRNA levels of pro-805 inflammatory mediators, and correlation between clinical scores and lung viral load or mRNA levels of pro-806 inflammatory mediators. 807

Fatal outcome of human influenza A (H5N1) is associated with high viral load 526 and hypercytokinemia

Pop-Vicas, Clinical review: primary influenza viral pneumonia

Intensive care adult patients with severe respiratory failure caused by Influenza A 530 (H1N1)v in Spain

Complications of viral influenza. The American journal 532 of medicine 121

Neuraminidase inhibitors for preventing and treating influenza in healthy adults 534 and children. The Cochrane database of systematic reviews

Late diagnosis of influenza in adult patients during a seasonal outbreak

Into the eye of the cytokine storm

A question of self-preservation: 540 immunopathology in influenza virus infection

Aberrant innate immune response in lethal infection of macaques with the 1918 542 influenza virus

Mucosal Immune Responses Predict Clinical Outcomes during Influenza 544

Infection Independently of Age and Viral Load

Chemokines, leukocyte trafficking, and inflammation. Current opinion in 547 immunology

Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19. 549

Targeting tumour necrosis factor to ameliorate viral pneumonia. The FEBS 551 journal

The cytokine storm of severe influenza and development of 553 immunomodulatory therapy

Tumor necrosis factor as a mediator of inflammation in influenza A 555 viral pneumonia

Genomic profiling of tumor necrosis factor alpha (TNF-alpha) receptor and 557 interleukin-1 receptor knockout mice reveals a link between TNF-alpha signaling and increased 558 severity of 1918 pandemic influenza virus infection

Oseltamivir (Tamiflu) and its potential for use in 598 the event of an influenza pandemic

Targeting ectromelia virus and TNF/NF-κB or STAT3 signaling for effective 601 treatment of viral pneumonia

Genetic resistance to smallpox: lessons 604 from mousepox

Pulmonary calcification following 607 smallpox handler's lung

A pneumonia outbreak associated with a new coronavirus of probable bat origin. 609

Estimates of global seasonal influenza-associated respiratory mortality: a 611 modelling study

Global influenza strategy 2019-2030 (World Health Organization

Collaborators, Mortality, morbidity, and hospitalisations due to influenza lower respiratory 614 tract infections, 2017: an analysis for the Global Burden of Disease Study

Efficacy of multiple-or single-dose cidofovir against vaccinia 617 and cowpox virus infections in mice

Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge

Effects of Treatment Delay on Efficacy of Tecovirimat Following Lethal Aerosol 621

Monkeypox Virus Challenge in Cynomolgus Macaques

The Treatment of Herpes Simplex Infections: An Evidence-Based 624

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial 626

Effect of dexamethasone on acute respiratory distress syndrome induced by the H5N1 628 virus in mice

Inhibition of the cytokine response does not protect 630 against lethal H5N1 influenza infection

Delayed antiviral plus immunomodulator treatment still reduces mortality in 633 mice infected by high inoculum of influenza A/H5N1 virus

Suppression of cytokine storm with a sphingosine analog provides protection 636 against pathogenic influenza virus

CCR2-antagonist prophylaxis reduces 639 pulmonary immune pathology and markedly improves survival during influenza infection

Peroxisome proliferator-activated receptor and AMP-642 activated protein kinase agonists protect against lethal influenza virus challenge in mice

H5N1 influenza virus pathogenesis in genetically diverse mice is mediated at the 645 level of viral load

Delayed clearance of viral load and marked cytokine activation in severe cases of 647 pandemic H1N1 2009 influenza virus infection

Inhibition of tumor necrosis factor reduces the severity 650 of virus-specific lung immunopathology

Correlations between lung proinflammatory cytokine 652 levels, virus replication, and disease after swine influenza virus challenge of vaccination-immune 653 pigs

Nasal cytokine and chemokine responses in experimental influenza A virus 655 infection: results of a placebo-controlled trial of intravenous zanamivir treatment. The Journal of 656 infectious diseases

Anti-TNF-α agents in the treatment of immune-mediated 658 inflammatory diseases: mechanisms of action and pitfalls

Inhibition of the inflammatory cytokine tumor necrosis factor-alpha with etanercept 660 provides protection against lethal H1N1 influenza infection in mice

Activities of oseltamivir and ribavirin used 663 alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and 664 B viruses

The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harbor 666 perspectives in biology

Hepatic acute phase proteins--668 regulation by IL-6-and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent 669 signaling

Crosstalk in NF-κB signaling pathways

Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription 673 by binding to NFkappaB

Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk 675 in cancer

Inflammatory regulatory network mediated by the joint action of 677 NF-kB, STAT3, and AP-1 factors is involved in many human cancers

Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors

Systemic corticosteroids and early administration of antiviral agents for pneumonia 682 with acute wheezing due to influenza A(H1N1)pdm09 in Japan

SARS-CoV-2 viral load is associated with increased disease severity and 684 mortality

Clinical features of patients infected with 2019 novel coronavirus in

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Influenza infection, SARS, MERS and COVID-19: 690 Cytokine storm -The common denominator and the lessons to be learned

Distinct roles for lymphotoxin-α and tumor necrosis factor in organogenesis and 693 spatial organization of lymphoid tissue

Influenza: propagation, quantification, and storage. Current 695 protocols in microbiology 29

A simple method of estimating fifty percent endpoints

Animals were killed on day 5 p.i. and lungs collected for analyses. Weight loss (A and B) and clinical 706 scores (C and D) were analyzed using two-way ANOVA with Sidak's post-tests and expressed as means

Viral load data (E) were log-transformed, analyzed using ordinary one-way ANOVA test with Fisher's 708 least significant difference (LSD) tests and expressed as means ± SEM. Histopathological scores (F), based 709 on microscopic examination of lung histology H&E sections (G), were examined using bright field

microscope on all fields at 400x magnification. Histopathological scores were analyzed by ordinary one-way 711

Lung histology sections (G-N) show 712 reductions in edema, leukocyte infiltration, and damage to alveolar septa in lungs of IAV-infected WT and 713 TM mice by etanercept treatment. *, p < 0.05; **, p < 0.01 and ***, p <0.001. Broken line in panel E 714 corresponds to the limit of virus detection. Bars in panel G-N correspond to 100 µm. TM, triple mutant mice 715 that express mTNF but not sTNF

Age-matched groups of WT, TNF -/-and TM (n = 720 4 or 5) female mice were infected with 3000 PFU IAV i.n., treated with oseltamivir (150 mg/kg), etanercept 721 (2.5 mg/kg) or a combination (combined) on days 3, 4 and 5 p.i., as indicated in panels A, E and I

Animals were monitored for weight loss (A, E and I) and clinical scores (B, F and J) until day 724

Data were analyzed by 725 two-way ANOVA with Sidak's post-tests and expressed as means ± SEM. Viral load (C, G and K) data was 726 log-transformed, analyzed using ordinary one-way ANOVA test followed by Fisher's LSD tests and 727 expressed as means ± SEM. Histopathological scores (D, H and L) were derived from microscopic 728 examination of lung histology H&E sections (presented in Fig. 3), analyzed using ordinary one-way ANOVA 729 test followed by Tukey's multiple comparisons tests and

001 and ****, p <0.0001. Broken lines in panels C, G and K correspond to the limit of virus 731

Animals were killed on day 6 p.i., lungs were 739 collected, fixed in 10% neutral buffered formalin, processed, embedded in paraffin blocks, sectioned, stained 740 with H&E and examined using bright field microscope on all fields at 400x magnification

Combined daily treatment with etanercept and high dose oseltamivir reduces expression of 745 inflammatory cytokines and chemokines and activation of STAT3

WT (n = 4 or 5) mice were infected 747 with 3000 PFU IAV i.n. and treated with oseltamivir (150 mg/kg) or etanercept or combined treatment on 748 days 3, 4, and 5 p.i. Animals were killed on day 6 p.i. and lungs collected for quantifying levels of expression 749 of selected cytokines and chemokines using qPCR (A-G). Protein levels of mTNF (H), pNF-κB p65 (I), and 750 pSTAT3 (J) were detected by western blotting (K) and quantified with the ImageJ software. For (K), samples 751 were run on 2 separate gels

s multiple comparisons tests and expressed as mean fold-change relative to the mock treated 753

Age-759 matched groups of WT and TNF -/-(n = 4 or 5) mice were infected with 3000 PFU IAV i.n. Animals were 760 treated with oseltamivir or etanercept or both drugs (combined) from day 3 p.i and treatment continued until 761 day 20 p.i., as indicated in panels A and B, where a purple arrow and a filled blue circle symbols indicate 762 oseltamivir and etanercept treatment days, respectively. Animals were monitored daily for weight loss (A 763 and B), clinical scores (C and D) and survival (E and F)

Survival for combined 769 treated animals was greater than 50% (i.e., 80%) at the last time point (day 21 p.i.), hence the median 770 survival time was >21 days (log-rank test, p = 0.0047 relative to mock-treated mice). Combined treatment 771 significantly increased median survival compared to etanercept

TNF -/-mice succumbed to infection on days 5-6 p.i. (F) and there were no 773 beneficial effects of the different treatment regimens as all IAV-infected mice

Weight loss (A and B) and clinical scores (C and D) data were analyzed using two-way ANOVA with Sidak's 775 post-tests and expressed as means ± SEM. Survival data (E) were analyzed by Log-rank

Data shown are from a single experiment

Combined treatment with high dose oseltamivir and S3I-201 reduces clinical scores, lung 779 viral load, pathology and downregulates mRNA transcripts for pro-inflammatory cytokines and 780 chemokines in IAV-infected mice. Age-matched groups (n = 5) of female WT mice were infected i

PFU IAV and treated with S3I-201 (5 mg/kg), oseltamivir (150 mg/kg), or both drugs

circle symbols indicate 783 oseltamivir and S3I-201 treatment days, respectively. For ethical reasons, animals were killed on day 5 p.i. 784 and lung tissue collected for various analyses. Weight loss (A) and clinical scores (B) were monitored until 785 day 5 p.i. Viral load (C) data was log-transformed and analyzed using ordinary

Histopathological scores (D) were derived from microscopic examination of the 787 lung histology H&E sections using bright field microscope on all fields at 400x magnification

Data are expressed as means ± SEM and were analyzed using two-way ANOVA (A and B

Tukey's multiple comparisons tests (A) and Dunnett's multiple comparisons tests (B) or ordinary one-way 790

mRNA transcript analysis was performed in 791 the separate experiment using the similar treatment strategy as described above. Gene expression levels 792 of the indicated cytokines and chemokines were quantified using qPCR (M-S). Data are expressed as mean 793 fold-change relative to the mock treated group ± SEM and were analyzed using

Sidak's multiple comparisons tests

Broken line 795 in panel C corresponds to the limit of virus detection